<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE303nnn/GSE303259/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Mus musculus</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303259</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>SRF fusion oncogenes encode constitutively activated chimeric transcription factors in myoid soft tissue tumors [C2C12]</name><description>SRF fusion genes result from chromosomal translocations in muscle-related soft tissue tumors, including perivascular tumors, myofibroma and rhabdomyosarcoma. SRF encodes the Serum Response Factor, a well-characterized transcription factor that dimerizes and associates with the cofactors TCF or MRTF to regulate muscle development. Here, we characterized four SRF fusion genes: SRF::RELA, SRF::FOXO1, SRF::ICA1L and SRF::PDGFRB. All fusions proteins were nuclear and dimerized through the SRF MADS box. SRF::RELA, SRF::FOXO1, and SRF::ICA1L acted as constitutively active transcription factors, independently of canonical cofactors. Their activity depended on the DNA-binding MADS box of SRF and the transactivation domain of the partner protein. We identified a cryptic transactivation domain within cytosolic ICA1L. These three SRF fusions promoted mesenchymal cell proliferation and upregulated muscle-related genes. They are representative of 98% of the identified SRF fusion cases. In contrast, SRF::PDGFRB activity relied on the tyrosine kinase domain and was sensitive to imatinib. SRF::PDGFRB acted as an oncogene in Ba/F3 cells, activated STAT1 signaling, and induced an interferon-like inflammatory response, in line with the inflammatory myofibroblastic tumor, in which that fusion was identified. In conclusion, SRF fusions constitute a novel family of oncogenes supporting cell proliferation and expression of muscle differentiation markers in myoid soft tissue tumors.</description><dates><publication>2026/07/18</publication></dates><accession>GSE303259</accession><cross_references><GSM>GSM9122051</GSM><GSM>GSM9122040</GSM><GSM>GSM9122050</GSM><GSM>GSM9122053</GSM><GSM>GSM9122042</GSM><GSM>GSM9122041</GSM><GSM>GSM9122052</GSM><GSM>GSM9122044</GSM><GSM>GSM9122043</GSM><GSM>GSM9122046</GSM><GSM>GSM9122045</GSM><GSM>GSM9122048</GSM><GSM>GSM9122037</GSM><GSM>GSM9122047</GSM><GSM>GSM9122039</GSM><GSM>GSM9122038</GSM><GSM>GSM9122049</GSM><GPL>24247</GPL><GSE>303259</GSE><taxon>Mus musculus</taxon></cross_references></HashMap>